Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial

BACKGROUND: Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in several advanced cancers. We report results from JAVELIN Solid Tumor JPN, a phase 1 trial of avelumab in Japanese patients with advanced solid tumors with expansion in patients with advanced gast...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Iwasa, Satoru, Muro, Kei, Satoh, Taroh, Hironaka, Shuichi, Esaki, Taito, Nishina, Tomohiro, Hara, Hiroki, Machida, Nozomu, Komatsu, Yoshito, Shimada, Yasuhiro, Otsu, Satoshi, Shimizu, Shin, Watanabe, Morihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570778/
https://www.ncbi.nlm.nih.gov/pubmed/30515672
http://dx.doi.org/10.1007/s10120-018-0903-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570778/
https://www.ncbi.nlm.nih.gov/pubmed/30515672
http://dx.doi.org/10.1007/s10120-018-0903-1

Ejemplares similares